ACOG committee opinion. Risk of breast cancer with estrogen-progestin replacement therapy.
Recent articles have examined the association between the use of combination estrogen-progestin regimens for hormone replacement therapy (HRT) and the risk of breast cancer. The objective of this Committee Opinion is to evaluate critically the presented evidence. Although epidemiologic studies suggest that the addition of progestins to estrogens may increase the risk of breast cancer, this increased risk has not been proved. The American College of Obstetricians and Gynecologists continues to recommend that HRT be considered as a treatment to relieve vasomotor symptoms and genitourinary tract atrophy and to reduce the risk of osteoporosis and, potentially, cardiovascular disease. Postmenopausal women should be apprised of the current understanding of the risks and benefits of HRT. When considering the use of HRT for longer than 5 years, the clinician and individual patient should weigh the benefits versus the potential side effects and risks for that particular patient.
D000368:Aged; D001940:Breast / Q000187:drug effects; D001943:Breast Neoplasms / Q000453:epidemiology*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011372:Progestins / Q000494:pharmacology; D012306:Risk
D004967:Estrogens; D011372:Progestins